What is Akelos?
Akelos Inc. is a biotechnology firm dedicated to pioneering novel non-opioid pharmaceuticals for the treatment of neuropathic pain. Addressing a critical public health need, the company aims to provide safe and effective alternatives to addictive opioid medications. Akelos is currently advancing its lead compound, AKE-1018, which has demonstrated promising preclinical efficacy in managing chronic neuropathic pain without the associated risks of dependence. The company's research and development efforts are bolstered by a collaboration with Weill Cornell Medicine and prior funding from the National Institutes of Health.
How much funding has Akelos raised?
Akelos has raised a total of $3.2M across 2 funding rounds:
Grant
$1.7M
Private Equity
$1.5M
Grant (2020): $1.7M with participation from National Institutes of Health
Private Equity (2026): $1.5M, investors not publicly disclosed
Key Investors in Akelos
National Institutes of Health
The National Institutes of Health (NIH) is a primary agency of the U.S. Department of Health and Human Services, responsible for biomedical and health-related research, providing crucial backing for scientific advancements.
What's next for Akelos?
The recent major strategic investment positions Akelos for significant growth and advancement in its drug development pipeline. This capital infusion is anticipated to propel the company through critical stages of clinical trials and regulatory processes for its lead non-opioid pain therapeutic. Akelos's focus on addressing the widespread issue of neuropathic pain, coupled with its innovative approach, suggests a strong market potential and a clear path toward commercialization. Future developments will likely involve expanding its research collaborations and potentially seeking further strategic partnerships to broaden its therapeutic offerings and market reach.
See full Akelos company page
